On August 17, 2018, the U.S. Food and Drug Administration (FDA) announced it had granted marketing approval to the BrainsWay Deep Transcranial Magnetic Stimulation System (TMS) for treatment of obsessive compulsive disorder (OCD). Currently, this device has FDA approval for the treatment of major depressive disorder, received in 2013. This clearance represents the first ever non-invasive medical device clearance for the treatment of OCD. The FDA reviewed data from a randomized, multi-center study of 100 people, of which 49 received treatment with the BrainsWay device and 51 received treatment with a non-working "placebo" device. Those already . . .